Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 26, 2019

View Archived Issues

Rocket Pharmaceuticals announces IMPD clearance of RP-L301 gene therapy

Sympathetic nervous system can protect from autoimmunity

A cure for the common cold, and paralysis

circRNA-104718 promotes hepatocellular carcinoma progression through miR-218-5p targeting

Galapagos initiates phase I trial with GLPG-3970

[68Ga]PCTA-DSPE radiolabeled chelator for atherosclerosis PET imaging

Antimelanoma DNA vaccine/oncolytic adenovirus combination greatly enhances vaccine efficacy

Ectopic expression of human melanopsin in RGCs restores visual function in animal models

Results presented from phase I/II MEVITEM study of vismodegib plus temozolomide

Promising cohort 1 data from phase I trial of ivosidenib and vorasidenib in IDH1-mutant glioma

SAP130 as novel noninvasive biomarker in Crohn's Disease

DL-001, a novel rapamycin analogue with highly selective mTORC1 inhibitor activity in vivo

First patient dosed in phase III TRuE-V clinical trial program of ruxolitinib cream

LIDDS presents preliminary data from phase IIb LPC-004 study of Liproca Depot

Promising interim data presented from phase I/IIa study of AstroRx cell therapy in patients with ALS

SARM1: a new therapeutic target for MS and other neurodegenerative disorders

New designer cytokine IC7Fc shows promise for type 2 diabetes

Inflazome divulges new NLRP3 inhibitors

PharmaResources discloses new HBV antivirals

Phase IIa study of EDP-305 in NASH meets primary endpoint

AzurRx reports phase II results for MS-1819 for exocrine pancreatic insufficiency in cystic fibrosis

Celgene International II Sarl synthesizes new PDE4 inhibitors

Tyme Technologies begins pivotal stage of TYME-88-Panc trial with SM-88

Beijing Scitech-Mq Pharmaceuticals divulges EGFR and HER2 inhibitors

Vaxart reports phase Ib data on oral bivalent norovirus vaccine

Sunshine Lake Pharma patents MAO-B inhibitors

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 31, 2026.
AIDS 2026: New targets for metabolic dysfunction despite ART
BioWorld
Although antiretroviral therapy (ART) can suppress HIV to undetectable levels, a growing body of evidence suggests that the virus leaves a lasting biological...
Tuojie Biotech (Shanghai) synthesizes new SARM1 inhibitors
BioWorld Science
Tuojie Biotech (Shanghai) Co. Ltd. has prepared and tested NAD(+) hydrolase SARM1 (SAMD2; MyD88-5) inhibitors found to be potentially useful for the treatment of...
Jingxin discloses new muscarinic and sigma receptor agonists
BioWorld Science
Shanghai Jingxin Biopharmaceutical Co. Ltd. and Zhejiang Jingxin Pharmaceutical Co. Ltd. have synthesized new muscarinic acetylcholine receptor and sigma receptor...
Death in Chinese gene-editing trial exposes ethical fault lines
BioWorld
The death of a 6-year-old girl after receiving an experimental brain-directed gene-editing therapy at the Xinhua Hospital in Shanghai has reopened debate over how...